Zacks Investment Research downgraded shares of Senseonics (NYSEAMERICAN:SENS) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

According to Zacks, “Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. “

Several other equities analysts also recently weighed in on SENS. UBS Group initiated coverage on shares of Senseonics in a research note on Tuesday, November 27th. They issued a sell rating for the company. Piper Jaffray Companies initiated coverage on shares of Senseonics in a research note on Tuesday, January 29th. They issued a neutral rating for the company. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Senseonics presently has an average rating of Hold and an average target price of $6.00.

SENS opened at $2.30 on Wednesday. Senseonics has a twelve month low of $2.15 and a twelve month high of $5.29.

Senseonics (NYSEAMERICAN:SENS) last posted its earnings results on Thursday, November 8th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $5.16 million. Senseonics’s revenue for the quarter was up 145.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.13) EPS.

A number of large investors have recently modified their holdings of SENS. Frontier Investment Mgmt Co. purchased a new position in Senseonics during the fourth quarter valued at approximately $52,000. Cerity Partners LLC grew its stake in Senseonics by 33.3% during the fourth quarter. Cerity Partners LLC now owns 20,000 shares of the company’s stock valued at $52,000 after acquiring an additional 5,000 shares in the last quarter. Nisa Investment Advisors LLC purchased a new position in Senseonics during the fourth quarter valued at approximately $64,000. United Bank purchased a new position in Senseonics during the third quarter valued at approximately $114,000. Finally, Raymond James Trust N.A. grew its stake in Senseonics by 11.4% during the fourth quarter. Raymond James Trust N.A. now owns 49,000 shares of the company’s stock valued at $127,000 after acquiring an additional 5,000 shares in the last quarter. 30.66% of the stock is owned by institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

See Also: What is the downside to momentum investing?

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.